News & Media | Lee's Pharmaceutical
20 DEC 2018

Auransa Enters into Exclusive Licensing Agreement with China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings, for Rights to AU018 in Greater China and Southeast Asia

PALO ALTO, CA, AND HONG KONG – December 19, 2018 – Auransa, Inc., an artificialintelligence (AI)-driven pharmaceutical company developing precision medicines in areas ofsignificant unmet medical need……





News & Media

Recent News and Release
20/10/2020
Zhaoke Ophthalmology and Nevakar Entered Into A License Agreement for NVK-002 — Introducing The Eye Treatment For Slowing The Progression of Myopia in Children in Greater China, SEA and South Korea Markets
Lee's Pharmaceutical Holdings Ltd. ("Lee's Pharm" or "the Company"; Hong Kong stock code: 0950.HK), a research-based biopharmaceutical company, is pleased to announce that a wholly owned subsidiary of its associated company, Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd (“ZKO”) has recently entered into an exclusive licensing agreement with Nevakar Inc. ("Nevakar"), a US-based privately held, late-stage, biopharmaceutical company developing multiple innovative medications in the ophthalmic and hospital injectable areasfor the development and commercialization of NVK-002 in Greater China (The People’s Republic of China (“PRC”), Hong Kong SAR, Macau SAR and Taiwan), South Korea and the Southeast Asian territories1. NVK-002 is a preservative-free, novel topical eye treatment for slowing the progression of myopia in children and is currently in a Phase 3 clinical trial study ("Childhood Atropine for Myopia Progression" or “CHAMP“ study) in the US and Europe.
Lee's Pharmaceutical Holdings Ltd. ("Lee's Pharm" or "the Company"; Hong Kong stock code: 0950.HK), a research-based biopharmaceutical company, is pleased to announce that a wholly owned subsidiary of its associated company, Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd...
know more
know more
25/07/2022
Lee’s Pharm proudly awarded again the “Caring Company Logo”
18/07/2022
Unicycive announces Exclusive License and Development Agreement with Lee’s Pharmaceutical Holdings Limited for Renazorb in China and certain other Asian markets
16/07/2022
Lee’s Pharm was honoured with “2021 Top 100 Chinese Chemical Pharmaceutical Companies” Award
16/07/2022
Lee’s flagship product Ferplex® was elected as “2022 Most Valuable Product in Partnership for Drug Store Chain in China”
30/06/2022
License Transfer from Solasia to Lee’s Pharm for the Sales Promotion of Sancuso® and episil® in three cities in China
21/06/2022
New product Teglutik® obtained Drug Registration Certificate
20/05/2022
New product Natulan® obtained Drug Registration Certificate
22/04/2022
New product “Nitric Oxide for Inhalation” (INOmax®) was approved for commercialization in China
12/04/2022
Signing of the Comprehensive Strategic Cooperation Agreement between Lee’s Pharm and Rongtai Pharmaceutical
05/04/2022
Launching of Lee’s Pharm Flagship Store on Ali’s and Jingdong’s e-commerce platforms in China
13/01/2022
Zhaoke-Hefei was honoured with the award of “2021 Anhui Provincial Role Model Enterprise in Consumer Products Industry”
01/01/2022
Listing on Guidance for Family Choice Pharmacy of Lee’s Pharm signature products — Ferplex® and Yallaferon®
01/01/2022
“STEM Experience Program for Secondary Students — Kanya Lee Scholarship Recognition Ceremony”
29/12/2021
Lee’s Pharm in-house product Yallaferon® was honoured with “2021 Biopharmaceutical Excellent Brand” Award
23/12/2021
Dr. Li Xiaoyi, the founder of Lee’s Pharm was recognized as “High-Level Talent in Guangzhou Nansha New Zone (Free Trade Zone)”
23/12/2021
Lee’s Pharm Mask Donation Campaign, Sending warmth and care to the community
17/09/2021
Zhaoke Oncology was honoured with “2020 Guangzhou High-end, Precision and Sophisticated Firms” Award
03/09/2021
Zhaoke-Hefei was honoured with the award of “Anhui Provincial High-End Brand Cultivation Demonstration Enterprise in Manufacturing Industry”
24/08/2021
Baptist’s Charity Campaign for World Vision International with sponsorship from Lee’s Pharm
23/08/2021
Patented Technology “Purification of Snake Venom from Viperidae” developed by Zhaoke-Hefei was honoured with “The 8th Anhui Provincial Patent Excellence Award”
26/07/2021
Lees Pharm was honoured with 2020 Top 100 ranking of Chinese Chemical Pharmaceutical Companies
24/06/2021
The New Product “Sodium Phenylbutyrate” from Lee’s Pharm — Bringing hope to rare disease patients — Lee’s Pharm participated in the Multidisciplinary Expert Seminar on Urea Cycle Disorders
07/06/2021
Lee’s Pharm attended the Rare Diseases Conference of Guangdong Medical Association
04/06/2021
Lee’s Pharm Sponsored Symposium at the Sexual Medicine Course for Providers of Women’s Health Care
21/10/2020
HKSTP InnoAcademy — Technology Leaders of Tomorrow programme
20/10/2020
Dr Benjamin Li, CEO of Lee’s Pharmaceutical Holdings Limited was interviewed by TVB on 15 October 2020 sharing our unique concept of mask production by Powder Pharmaceuticals Incorporated (Interview Video)
20/10/2020
Zhaoke Ophthalmology and Nevakar Entered Into A License Agreement for NVK-002 — Introducing The Eye Treatment For Slowing The Progression of Myopia in Children in Greater China, SEA and South Korea Markets
11/10/2020
Concludes Series B Fundraising of approximately US$145 million for Zhaoke Ophthalmology — Marks Big Step Towards Achieving Possible Spin-off and Separate Listing
10/03/2020
HKBIO and Lee’s Pharm Mask Donation Campaign
03/03/2020
Donation of ERT-PCR Technology for New Coronavirus Detection Press Conference
30/10/2019
Lee’s Pharm Cardiovascular Products Meeting of the 30th GW-ICC
29/10/2019
Greater Pediatrics, Greater Kids, Greater China ——Ferplex of Lee’s Pharmaceutical Holdings Ltd. appeared in the 24th Congress of Chinese Pediatric Society
21/10/2019
Pre-IND meeting to communicate the combination of recombinant fully human anti- PD-L1 monoclonal antibody injection (ZKAB001 for short) and vaccinia GM-CSF/TK inactivated virus (Pexa-Vec, oncolytic virus)
14/10/2019
Building a Bridge; China-Italy Cooperation in Medical Education
24/09/2019
Wen Guohui, Deputy Secretary of the CPC Guangzhou Municipal Committee and Mayor of Guangzhou visited Zhaoke Pharmaceutical (Guangzhou) Ltd.
09/09/2019
Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd.had a very successful meeting with the reviewers from the Center for Drug Evaluation of NMPA of China
01/09/2019
East Meets West – Lee’s Pharm 9th Perinatal Medical Forum in Beijing
20/08/2019
INOMAX pre-NDA meeting
02/04/2019
RegeneRx and Lee’s Pharm to Accelerate RGN-259 Development in China
20/12/2018
Auransa Enters into Exclusive Licensing Agreement with China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings, for Rights to AU018 in Greater China and Southeast Asia
06/09/2018
SillaJen and Lee’s Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in ChinaPhase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer